Avelumab & #43; Axitinib Approved for Treatment of Renal Cell Carcinoma

THURSDAY, May 16, 2019 -- Avelumab (BAVENCIO) was approved this week for first-line treatment of advanced renal cell carcinoma (RCC) in combination with axitinib, the U.S. Food and Drug Administration announced. The agency based the approval on data...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news